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DNMT3aWhile the methylation machinery of mammalian cells has been shown to be capable of both maintenance
and de novo methylation at CpNpG sites, CpNpG methylation in the human genome has not been
demonstrated. Here, we report the ﬁrst observation of 5-methylcytosines in CpNpG triplets in the human
genome. We identify the existence of CpNpG methylation in a number of genes which contain trinucleotide
repeat regions, including the androgen receptor (AR). We further analyzed DNA extracted from primary
tissue samples and found the same pattern of CpNpG methylation. To conﬁrm our results, we performed
Southern blot analysis by analyzing the cleavage sites of restriction enzymes within exon 1 of the AR gene
and found direct evidence of the presence of 5mCs in CpNpG triplets in the human genome. Our results also
suggest that this methylation pattern may be due to the human DNA methyltransferases DNMT1 and
DNMT3A. Although the functional signiﬁcance needs to be tested further, the discovery of inheritable CpNpG
methylation in the human genome may have important implications in our understanding of gene regulation
and of the development of various diseases, including cancer.at Department of Otolaryngol-
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1.
cmoon5@jhmi.edu (C. Moon).
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Methylation of cytosine residues in prokaryotic and eukaryotic
genomes is an important epigenetic mechanism in gene regulation
[1–4]. It is generally believed that cytosine methylation occurs
exclusively in CpG dinucleotides in mammalian genomes [4–6]. In
contrast, in plant genomes, 5-methylcytosines (5mC) in CpNpG
triplets is as frequent as in CpG dinucleotides, where N can be any
base and the methylcytosine occurs at a symmetrical sequence [7].
The existence of CpNpG methylation in mammalian genomes in vivo
remains contentious. While data derived from nearest neighbor
analysis suggests that a considerable proportion of 5mC was not
located exclusively in CpG dinucleotides, the data from genomic
sequencing of mammalian DNA has not uncovered abundant
methylation at non-CpG sites [8–13]. These consistencies have been
partially answered by Clark et al. who demonstrated that the
methylation machinery of mammalian cells has been found to be
capable of both maintenance and de novomethylation at CpNpG sites
[14]. However, they failed to demonstrated CpNpG methylation inmammalian genomes although such methylation was identiﬁed
within a stably integrated segment of plasmid DNA. In this report,
using bisulﬁte sequencing and Southern blot analysis, we provide
direct evidence demonstrating the presence of 5mCs in CpNpG triplets
in the human genome.
Results
Presence of CpNpG methylation in cell lines
To determine if CpNpG methylation is present in the human
genome, we screened 29 genes; 22 were encoded in the nuclear
genome while 7 were encoded in the mitochondrial genome
(Table 1). Fifteen of these genes contained a CpNpG trinucleotide
repeat region. Using the bisulﬁte sequencing approach, we analyzed
the methylation status of these genes in a number of cancer cells lines
of different origins. The large array of cell lines was used to determine
if CpNpG methylation was tissue-speciﬁc, a phenomenon that is seen
with some CpG methylation. Genomic DNA from the 35 cancer cell
lines were treated with sodium bisulﬁte which converted unmethy-
lated cytosine residues to uracils while methylated cytosine residues
resisted such treatment. Sodium bisulﬁte-modiﬁed DNA was ampli-
ﬁed using PCR primers designed according to sequences not affected
by methylation. Of these 29 genes, 6 demonstrated extensive CpNpG
Table 1
Summary of genes examined, primer sequences for bisulﬁte sequencing, and CpNpG methylation status. MT: mitochondrial genome. M: CpNpG methylation present. U: no CpNpG
methylation present.
Gene Locus Forward primer (5′→3′) Reverse primer (5′→3′) Methylation status
AIB1 (NCOA3) 20q12 AGGGTTTTTTTAATGTTTAAATGGT ATCCTGCCAAAACCCATCCATACT M
AR X AAGATTTATTGAGGAGTTTTTTAGAAT AATAACCTATAAAACCTCTACAATAAA M
ASH1 (ASCL1) 12q22–q23 GAAAGTTTTGTTAAGATGGAGAG CAAAACCCAAATTAACCAAC M
BHLHB5 (BHLHE22) 8q13 GAGGGGTGTTTTAATGTTTATT CCTTTTACTCTTTAAATTTCTTACT U
BRCA1 17q21 AGTTTATGGGAAGTAGTTATGTATTTTAGG CTAAAATAATATTCCTAAAATACCTTTACC U
DMPK 19q13.2–q13.3 TTGTTTTGAGTGTGGGTTTT AACCCAACTTACTACCTTCC U
DRPLA (ATN1) 12p13.31 GTGTGGAGTTAGGGTTTTT AAACCATTAAAACCTACTTAACTATAA U
E2F4 16q22.1 GGGGGTTATTATTGTAGTGA CCTTAATAAACTCAAAAAAA U
GAGE7B (GAGE12I) X GTGGGATTTTTTTATTTTTAAT ACTACCTCACAACTCCCTAAC U
H19 11p15.5 TGTTTTTTGAGGGGAGATAGTGGTTTGGGA AATATCCCTCATAAACTC U
HD (HTT) 4p16.3 GATTTTGGAAAAGTTGATGAAGGT AATATCCCTCATAAACTC U
NOTCH4 6p21.3 GGATTGGGGTTTGGAGAA TAAAAATCTCCTCCATCCA U
POLG 15q25 AAAAGAAGTTAAGTTGGAGTTT ACATCTCCCCTCCTTACC U
RAI1 17p11.2 TTATTTTTATAAGAGTTGTA TAAAAAATTTCCTAAACATA U
SCA1 (ATXN1) 6p23 AGTTTATTGGGTTTTTTTAA ACCCCCAAATAATAAACCCC M
SCA2 (ATXN2) 12q24 TGTATGGGTTTTTTATTATG CCTCATATTTACATAAATTCCATCAA U
SCA3 (ATXN3) 14q24.3–q31 TGATAGGTTATTTTGTGATGAAA CTAAATCACTCCCAAATACTCC M
SCA7 (ATXN7) 3p21.1–p12 GGTTGTGGATGATGTTAGGG TAAAAACCTCAACCCACAAA U
SCA8 (C10orf2) 13q21 AGTATGAGGAAGTATGGAAAAA TCCCAATTCCTTAACTAAACC M
SCA12 (PPP2R2B) 5q31–q33 AGGGGAGGAGGTTGGAAGAG ACTCACCCTCACACCCACAC U
SCA17 (TBP) 6q27 GTTTATTTTGGAAGAGTAATAAAGG AATACCTAACCTAAAATTCCCTA U
ATP6 (MT-ATP6) MT GGGTGTAGTGATTATAGGTT AACTCTTCCAATTAAATACA U
COX1 (MT-CO1) MT GGGAATTATTTTTATTTTGGAG AAAAACCAATTAATATCATAACTCA U
COX2 (MT-CO2) MT TTGGTTATTAATGGTATTGAATTT AACATAAAACTATAATTTACTCCACA U
COX3 (MT-CO3) MT GATTTTTGGTTTAGTTATGTGA AAACCACATCTACAAAATACCA U
CYTB (MT-CYB) MT TTATTTTGAGGGGTTATAGTAAT CAAAAACTCCTCCTAATTTAT U
ND1 (MT-ND1) MT AATTGTAATGGTATTTTTAATGTTT TCTAATATTAAAACCTAAAACTAATTC U
ND5 (MT-ND5) MT ATTTATGTGTTTAGATTAAGAAGTT TTTTAAATAATCCTCCTATTTTTC U
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androgen receptor (AR) gene, one of the two alleles from each cell line
was unmethylated in most of the CpG sites and in all CpNpG sites in
the genomic region (Figs. 1a and b). The other allele showed extensive
CpG methylation consistent with the nature of an inactivated X
chromosome. In addition, we observed several 5mCs in the CpNpG
sites in the latter allele, including three consecutive CTG sites and two
CAG sites (Fig. 1a). Interestingly, we observed this methylation
phenomenon only in genes with trinucleotide repeat regions (Table 1,
Figs. 1a and b). Furthermore, we found that this pattern of
methylation was associated with the trinucleotide repeat region;
sequencing of the other regions did not demonstrate 5mCs in CpNpG
sites (data not shown). It should be noted that the sequencing did not
demonstrate tissue speciﬁcity; while CpNpG methylation was not
observed in every cell line examined, it was seen in cell lines of
differing origins. For example, methylation of the trinucleotide region
of the AR genewas observed in both lung cancer cell lines and prostate
cancer cell lines (data not shown).Presence of CpNpG methylation in tissues
Because it is believed that DNA methylation patterns can be
signiﬁcantly altered in cell culture conditions and in particular
because DNA methylation density can be increased, we analyzed
constitutional DNA extracted from 30 head and neck tumor samples,
30 lung tumor samples, and 8 normal lung tissue samples. Similar to
our examination of CpNpG methylation in cancer cell lines, a large
number of primary tissue samples were sequenced to determine if
there was a difference in CpNpG methylation between normal and
tumor samples. We observed CpNpGmethylation in tissue samples as
well (Table 1, Fig. 1b). However, the sequencing did not demonstrate
a difference in CpNpG methylation between normal tissue samples
and tumor samples. The result indicates that the 5mCs in CpNpG sites
are found not only in culture conditions but are also found naturally inthe human genome. These data, therefore, provide direct evidence of
the presence of 5mCs in CpNpG triplets in the human genome.
Conﬁrmation of CpNpG methylation by Southern blot analysis
To conﬁrm our results, we performed Southern blot analysis. As
shown with the AR in Fig. 2a, a roughly 3.8-kilobase (kb) fragment
including the relevant methylation region could be generated by AccI
(GT↓MKAC) digestion. Four PstI sites (CTGCA↓G) were identiﬁed
within the 3.8-kb fragment (located at 34 bp, 856 bp, 1125 bp, and
1580 bp distant to the proximal AccI site) (Fig. 2a). Because the
restriction enzyme PstI is methylation-sensitive (it cannot cleave the
site if the 5′ cytosine is a 5mC), we predicted that the PstI site located
at 856 bp distant to the proximal AccI site could not be cleaved due to
CTG methylation. Genomic DNA samples were digested by AccI alone
or AccI plus PstI, followed by Southern blot analysis using a 572-bp
DNA probe located between the ﬁrst two PstI sites (Fig. 2a). When
DNA was digested by AccI alone, only a single 3.8-lb band could be
detected in all four specimens as predicted (Fig. 2b). When DNA was
digested by AccI and PstI, two bands, 0.8-kb and 1.1-kb, were
observed in each of the specimens (Fig. 2b). This pattern was
consistent with our prediction that the second PstI site could not be
cleaved by PstI in one of the two alleles because of the presence of a 5′
5mC (Fig. 1b). The lack of any band at the 3.8-kb and 1.5-kb positions
indicated that the most distal PstI site was completely unmethylated
in both alleles, and that enzymatic cleavage was complete.
CpNpG methylation may be mediated by DNMT1 and DNMT3a
There are four members of the human DNA methyltransferase
(DNMT) family: DNMT1, DNMT2, DNTM3A, and DNMT3B. While the
methylation machinery of mammalian cells has been shown to be
capable of both maintenance and de novomethylation of CpNpG sites,
it has not been conclusively determined which DNA methyltransfer-
ase is responsible [14]. To determine which DNMT is associated with
Fig. 1. Bisulﬁte sequencing analysis. (a) Representative bisulﬁte sequencing results in cell lines are shown for each gene which demonstrated CpNpGmethylation. (b) Representative
bisulﬁte sequencing results in primary tissue samples are shown for each gene which demonstrated CpNpG methylation.
69J. Lee et al. / Genomics 96 (2010) 67–72
Fig. 2. Southern blot analysis for DNA methylation status within exon 1 of the AR gene.
Constitutional DNA from 4 women were analyzed. (a) Restriction enzyme map in the
region of the AR gene. Positions of each enzymatic cleavage site are indicated according
to sequences in GenBank accession number AL049564. Approximate distances from the
restriction enzyme cleavage sites to the ﬁrst AccI site are indicated. The location of the
probe for hybridization is also indicated. (b) The results of Southern blot analysis. A,
genomic DNA cleaved only with AccI; A/P, genomic DNA cleaved with both AccI and
PstI. The approximate sizes of DNA fragments are indicated on the right side.
Fig. 3. DNMT-speciﬁc inhibition and demethylation. (a) H1944 cells were treated for
10 days with 75 nM of siRNA designed against DNMT1, DNMT2, DNMT3A, or DNMT3B
(lane A) andwith controls of scrambled siRNA (lane B), transfection reagent alone (lane
C), and completely untreated (lane D). After 10 days, there was signiﬁcant depletion of
the respective DNMTs, both at the level of mRNA and protein. Treatment with the
scrambled siRNA and the transfection agent alone did not deplete any of the DNMTs.
GAPDH and β-actin were used as controls for loading. (b) The CpNpG methylation
status of the AR was determined through sodium bisulﬁte sequencing of the DNA from
these siRNA-treated cell lines. Cells treated with DNMT1 and DNMT3A siRNA
demonstrated demethylation of exon 1 of the AR while cells treated with DNMT2 and
DNMT3B siRNA and the controls remained methylated.
70 J. Lee et al. / Genomics 96 (2010) 67–72CpNpG methylation in humans, siRNA were designed for DNMT1,
DNMT2, DNMT3A, and DNMT3B. Three lung cancer cell lines, NCI-
H1944, NCI-H1975, and NCI-H292, were treated with DNMT siRNA at
a concentration of 75 nM for 10 days. RNA, DNA, and protein were
extracted on days 1, 5, and 10. After 10 days of treatment, we
observed substantial depletion in expression of all four DNMTs
(Fig. 3a). We then analyzed the methylation status of the 6 genes
exhibiting CpNpG methylation in the siRNA-treated cells using the
bisulﬁte sequencing method. After 1 day of treatment, there was no
change in the methylation status of these genes (Fig. 3b). After
10 days, however, we observed considerable demethylation of CpNpG
sites in cells treated with DNMT1 and DNMT3A siRNA while no
change in the methylation status was observed in cells treated with
DNMT2 or DNMT3B siRNA (Fig. 3b). These results seem to implicate
DNMT1 and DNMT3A in CpNpG methylation.
Discussion
While the methylation machinery of mammalian cells has been
shown to be capable of both maintenance and de novo methylation
at CpNpG sites [14], CpNpG methylation in mammalian genomes
has not been demonstrated. While studying the methylation
patterns in the human androgen receptor gene for clonality analysis,
we had identiﬁed initial evidence of CpNpG methylation in tumor
cell lines [17]. Through a further expansion of this initial
observation, this report provides deﬁnitive evidence for the
presence of 5mCs in CpNpG triplets in the human genome. Using
bisulﬁte sequencing, abundant CpNpG methylation was found in cell
lines and tissues. Our results also demonstrated that CpNpG
methylation occurred predominantly in genes with polymorphic
repeat regions and was seen only in the trinucleotide repeat
regions. Furthermore, to avoid possible sequence and other artifacts,our results were conﬁrmed by Southern blot analysis. Finally,
treatment with various siRNA designed against the DNMT1, 3A, and
3B determined that CpNpG methylation appears to be mediated by
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unequivocally demonstrating the evidence of CpNpG methylation in
mammalian genomes, and is certainly consistent with a prior
prediction from the ﬁnding of methylation machinery in the
mammalian cell lines [14].
So far, it is generally believed that non-CpG dinucleotide
methylation (cytosine methylation at CpA or CpT) is prevalent almost
exclusively in embryonic stem cells and negligible tissues and that it is
mediated by DNA methyltransferase 3A [16]. However, the functional
signiﬁcance of non-CpG dinucleotide methylation during the early
stage of development is quite uncertain. Likewise, although recent
studies showed that methylation of the outer cytosine residue of a
CpCpG site can block Sp1 binding, resulting in transcriptional
suppression [17], the functional signiﬁcance of symmetrical CpNpG
methylation has not been explained. Thus far, we have observed
CpNpG methylation only in trinucleotide repeat regions and it is
possible that methylation of the repeat region plays a protective role
against the expansion of these trinucleotide repeats. While the
signiﬁcance of this pattern of methylation has yet to be determined,
the discovery of inheritable CpNpGmethylation in the human genome
may have important implications in our understanding of gene
regulation and of the development of diseases, including the
carcinogenic process and inheritable neurological conditions.
Materials and methods
Cell lines and tissues
We analyzed a panel of cancer cell lines: 16 lung cancer cell lines
(A549, H1299, H1437, H1563, H1568, H1650, H1703, H1838, H1944,
H1975, H2030, H226, H292, H23, H522, and H838), 10 head and neck
cancer cell lines (011, 012, 013, 019, 022, 028, Fadu, KYSE30, KYSE410,
and KYSE520), and 4 colorectal cancer cell lines (DLD, HCT116 p53+/+,
HCT116 p53−/−, and SW480). The lung cancer cell lines and nine head
and neck cancer cell lines (011, 012, 013, 019, 022, 028, KYSE30,
KYSE410, and KYSE520) were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS), penicillin, and
streptomycin. The head and neck cancer cell line FaDu was cultured in
Dulbecco's Modiﬁed Eagle's Medium supplemented with 10% FBS,
penicillin, and streptomycin. The colorectal cancer cell lines
HCT116 p53 +/+, HCT116 p53−/−, and DLD1 were cultured in
McCoy's 5A medium supplemented with 10% FBS, penicillin, and
streptomycin while SW480 was cultured in Leibovitz L-15 medium
with 10% FBS, penicillin, and streptomycin. The lung cancer cell
lines as well as FaDu, DLD1, and SW480 were purchased from the
American Type Culture Collection. The colorectal cancer cell lines
HCT116 p53 +/+ and HCT116 p53−/− were generously provided
by Dr. Bert Vogelstein of The Johns Hopkins University while the
head and neck cancer cell lines KYSE30, KYSE410, and KYSE520
were kindly provided by Dr. Shimada of Kyoto University. The head
and neck cancer cell lines 011, 012, 013, 019, 022, and 028 were
developed from the culture of primary HNSC in the Division of Head
and Neck Cancer Research at The Johns Hopkins University.
30 primary lung tumor tissues, 30 primary head and neck tumor
tissues, and 8 primary normal lung tissues were collected after
surgical resections with prior consent from patients in The Johns
Hopkins University Hospital as per institutional review board-
approved protocols.
DNA extraction and bisulﬁte sequencing
Genomic DNA was extracted using phenol-chloroform extraction
and ethanol precipitation in the presence of glycogen. One microgram
of DNA from each cell line or tissue was used in the initial step of
chemical modiﬁcation. Brieﬂy, DNA was denatured by NaOH and
treated with hydroquinone and sodium bisulﬁte (Sigma, St. Louis,Missouri). After puriﬁcation using Wizard DNA puriﬁcation resin
(Promega, Madison, Wisconsin), the DNA was treated again with
NaOH. After precipitation, the DNA was recovered in water and ready
for PCR using speciﬁc primers for amplifying both methylated and
unmethylated sequences of each gene. The primer sequences are
listed in Table 1. PCR reactions were carried out in a 50-µl volume
containing about 50 ng of modiﬁed DNA, 3% dimethylsulfoxide,
200 µM of dNTP, 1.5 mM of MgCl2, 0.4 µM of PCR primers, and
1.25 U of Taq DNA polymerase (GIBCO BRL, Gaithersburg, Maryland).
The DNA was ampliﬁed for 35 cycles at 95 °C for 30 s, 60 °C for 60 s,
and 70 °C for 60 s followed by a 5-min extension at 70 °C in a
temperature cycler (Hybaid, Omnigene, Woodbridge, New Jersey) in
500-µl plastic tubes. PCR products were separated on 2% agarose gels
and visualized after staining with ethidium bromide. For each DNA
sample, primer sets for methylated DNA and unmethylated DNAwere
analyzed.
A TA cloning kit (Invitrogen, Carlsbad, California) was used to
clone the AR gene segment. One µl of fresh PCR products containing
both methylated and unmethylated sequences were cloned into the
TA vector as speciﬁed by the manufacturer. For sequencing, 500 ng of
plasmid DNA containing inserts was used as a template for a reaction
with an Ampicycle sequencing kit (Perkin Elmer, Boston, Massachu-
setts). The T7 primer for vector sequence was end labeled. Cycling
conditions were followed as speciﬁed by the manufacturer.
Southern blot analysis
Genomic DNA was isolated from cell lines and from lung tissue
samples from female patients by proteinase-K digestion (0.1 mg/ml)
overnight at 50 °C followed by phenol-chloroform extraction and
ethanol precipitation. For AccI digestion, 10 µg of genomic DNA from
each sample was digested using restriction enzyme AccI (20U)
(Promega, Madison, Wisconsin) for 2 h at 37 °C in a 50-µl reaction
volume and additional 10 U were added for an overnight digestion.
For AccI plus PstI digestion, AccI digested genomic DNA was further
digested with 10U of PstI (GIBCO BRL, Gaithersburg, MD) for 2 h and
additional 10 U of the enzyme was added for an overnight digestion.
Digested genomic DNA from each sample was separated by
electrophoresis on a 0.8% agarose gel. DNA was transferred to a
nitrocellulose membrane (Amersham Life Science, Inc., Arlington
Heights, Illinois) and then ﬁxed by UV cross-linking. Following
prehybridization in Rapid-Hyb buffer (Amersham Life Science, Inc.)
for 1 h, the membrane was hybridized for 3 h with a radioisotope-
labeled DNA probe. The Probe was synthesized by PCR ampliﬁcation
of a 572-bp DNA fragment from positions 34,093–34,664 (GenBank
accession number: AL049564) (Fig. 2A) and labeled with γ[32p]dGTP
using a random primer labeling kit (Promega) according to the
manufacturer's protocol. The membrane was washed sequentially
with 1× SSC/0.1% SDS at (65 °C for 30 min.), then 0.1× SSC/0.1% SDS
(65→°C for 30 min.) and exposed to autoradiography ﬁlms.
siRNA treatment
siRNA were synthesized using the Silencer siRNA Construction Kit
(Ambion) according to the manufacturer's instructions. The
sequences of the DNMT1 siRNA templates are 5′-ACACATGTGAACG-
GACAGATTCCTGTCTC-3′ (antisense) and 5′-TCTGTCCGTTCA-
CATGTGTTTCCTGTCTC-3′ (sense). The sequences of the DNMT2
siRNA templates are 5′-AAGACGATTGAAGGCATTACACCTGTCTC-3′
(antisense) and 5′-AATGTAATGCCTTCAATCGTCCCTGTCTC-3′ (sense).
The sequences of the DNMT3A siRNA templates are 5′-AAG-
CACCCCCCGGTGGAAAGCCCTGTCTC-3′ (antisense) and 5′-AAGCTTTC-
CACCGGGGGGTGCCCTGTCTC-3′ (sense). The sequences of the
DNMT3B s iRNA templa tes are 5 ′ -CTCTAGGCATCCGT-
CATCTTTCCTGTCTC-3′ (antisense) and 5′-AGATGACGGATGCCTA-
GAGTTCCTGTCTC-3′ (sense). The sequences of the scrambled siRNA
72 J. Lee et al. / Genomics 96 (2010) 67–72templates are 5′-AATCGACCTCTGGAGCTAGCGCCTGTCTC-3′ (anti-
sense) and 5′-AACGCTAGCTCCAGAGGTCGACCTGTCTC-3′ (sense).
Cells were transfected with 75 nM of siRNA using Lipofectamine
(Invitrogen) according to the manufacturer's instructions.
RNA extraction and RT-PCR analysis
Total RNA was extracted with Qiazol (Qiagen). Samples were
treated with DNase I before reverse transcription using random
priming and Superscript Reverse Transcriptase (Life Technologies),
according to the manufacturer's guidelines. DNMT1, DNMT2,
DNMT3A, and DNMT3b RT-PCR analyses were performed as previ-
ously described [15,16]. As an internal control, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was ampliﬁed with 24 cycles to
ensure cDNA quality and quantity for each RT-PCR. PCR was
performed in a DNA thermal cycler (Perkins-Elmer Co.). The ﬁnal
PCR products were resolved on a 2% TBE agarose gel and visualized
using ethidium bromide staining.
Western blot analysis
Cells were lysed in 100 µl of M-PER cell lysis buffer (Pierce)
supplemented with 1 mM phenylmethylsulfonyl ﬂuoride, 10 mM
sodium orthovanadate, and complete protease inhibitor cocktail
(Roche Molecular Biochemicals) according to the manufacturer's
instructions. Protein concentration was determined by the bicincho-
ninic acid assay (Pierce). Equivalent amounts of protein (50 µg/lane)
were electrophoresed on 8% SDS–polyacrylamide gel. The gel was
electroblotted onto nitrocellulose membrane and probed with the
appropriate antibodies (DNMT1, 1:2000, New England Biolabs;
DNMT2, 1:250, Abgent; DNMT3A, 1:500, Abcam; and DNMT3B,
1:500, Abcam). The membranes were visualized using
chemiluminescence.
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